Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Hatz

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Pharmaceuticals (Basel, Switzerland)|September 28, 2024
Intravitreal Dexamethasone Implant in Anti-Vascular Endothelial Growth Factor Pretreated Diabetic Macular Edema-A Swiss Cohort StudyFerhat Turgut, Gábor M Somfai, Christoph Tappeiner, et al.
Ophthalmic Research|July 16, 2025
Association of Localized Retinal Sensitivities with Spectral-Domain Optical Coherence Tomography-Derived Morphologic Data in Macular Subfields in Age-Related Macular DegenerationInês P Marques, Ana C Almeida, Stefan Futterknecht, et al.
Ophthalmology Science|September 10, 2024
Artificial Intelligence-Based Disease Activity Monitoring to Personalized Neovascular Age-Related Macular Degeneration Treatment: A Feasibility StudyZufar Mulyukov, Pearse A Keane, Jayashree Sahni, et al.
Eye (London, England)|May 13, 2026
I-SCREEN: Development of an AI-based infrastructure for community-wide screening and prediction of progression in age-related macular degeneration providing accessible shared careMarie Louise Enzendorfer, Gregor S Reiter, Hrvoje Bogunović, et al.
Ophthalmology and Therapy|June 23, 2026
Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network ReportKatharina Heck, Katja Hatz, Marco Cattaneo, et al.
BMJ Open Ophthalmology|January 30, 2026
First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network reportAmr Saad, Christina Plasencia, Justus Garweg, et al.
Ophthalmology and Therapy|October 17, 2025
One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportAnne Tillmann, Richard Stillenmunkes, Justus G Garweg, et al.
Ophthalmology Science|March 5, 2026
Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network ReportJan Spindler, Dmitri Artemiev, Isabel B Pfister, et al.
Ophthalmology and Therapy|March 4, 2026
One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportAlice M Kitay, Anne Tillmann, Isabel Pfister, et al.
Ophthalmology. Retina|March 26, 2025
One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportGabriela Grimaldi, Aude Ambresin, Isabel B Pfister, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Pharmaceuticals (Basel, Switzerland)|September 28, 2024
Intravitreal Dexamethasone Implant in Anti-Vascular Endothelial Growth Factor Pretreated Diabetic Macular Edema-A Swiss Cohort StudyFerhat Turgut, Gábor M Somfai, Christoph Tappeiner, et al.
Ophthalmic Research|July 16, 2025
Association of Localized Retinal Sensitivities with Spectral-Domain Optical Coherence Tomography-Derived Morphologic Data in Macular Subfields in Age-Related Macular DegenerationInês P Marques, Ana C Almeida, Stefan Futterknecht, et al.
Ophthalmology Science|September 10, 2024
Artificial Intelligence-Based Disease Activity Monitoring to Personalized Neovascular Age-Related Macular Degeneration Treatment: A Feasibility StudyZufar Mulyukov, Pearse A Keane, Jayashree Sahni, et al.
Eye (London, England)|May 13, 2026
I-SCREEN: Development of an AI-based infrastructure for community-wide screening and prediction of progression in age-related macular degeneration providing accessible shared careMarie Louise Enzendorfer, Gregor S Reiter, Hrvoje Bogunović, et al.
Ophthalmology and Therapy|June 23, 2026
Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network ReportKatharina Heck, Katja Hatz, Marco Cattaneo, et al.
BMJ Open Ophthalmology|January 30, 2026
First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network reportAmr Saad, Christina Plasencia, Justus Garweg, et al.
Ophthalmology and Therapy|October 17, 2025
One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportAnne Tillmann, Richard Stillenmunkes, Justus G Garweg, et al.
Ophthalmology Science|March 5, 2026
Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network ReportJan Spindler, Dmitri Artemiev, Isabel B Pfister, et al.
Ophthalmology and Therapy|March 4, 2026
One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportAlice M Kitay, Anne Tillmann, Isabel Pfister, et al.
Ophthalmology. Retina|March 26, 2025
One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportGabriela Grimaldi, Aude Ambresin, Isabel B Pfister, et al.
Pageof 5